Pages that link to "Q39641387"
Jump to navigation
Jump to search
The following pages link to Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication (Q39641387):
Displaying 50 items.
- A Perspective of Immunotherapy for Prostate Cancer (Q26741277) (← links)
- New Strategies for the Treatment of Solid Tumors with CAR-T Cells (Q26748500) (← links)
- Chimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and Prospects (Q26753082) (← links)
- Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy (Q26773309) (← links)
- Novel immunotherapies in lymphoid malignancies (Q26777394) (← links)
- Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors (Q26778759) (← links)
- Adoptive immunotherapy for acute leukemia: New insights in chimeric antigen receptors (Q26795540) (← links)
- Strategies for combining immunotherapy with radiation for anticancer therapy (Q26796675) (← links)
- CAR T Cell Therapy: A Game Changer in Cancer Treatment (Q26822769) (← links)
- PSMA-specific CAR-engineered T cells eradicate disseminated prostate cancer in preclinical models (Q27339832) (← links)
- CAR therapy: the CD19 paradigm (Q28081642) (← links)
- Smart CARs engineered for cancer immunotherapy (Q28087236) (← links)
- Designing chimeric antigen receptors to effectively and safely target tumors (Q28088526) (← links)
- Progress and problems with the use of suicide genes for targeted cancer therapy (Q28262370) (← links)
- Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma (Q28537688) (← links)
- An Optimized GD2-Targeting Retroviral Cassette for More Potent and Safer Cellular Therapy of Neuroblastoma and Other Cancers (Q28551080) (← links)
- Redirecting Specificity of T cells Using the Sleeping Beauty System to Express Chimeric Antigen Receptors by Mix-and-Matching of VL and VH Domains Targeting CD123+ Tumors (Q28553650) (← links)
- The advantages of PD1 activating chimeric receptor (PD1-ACR) engineered lymphocytes for PDL1(+) cancer therapy (Q28646882) (← links)
- CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia (Q29620607) (← links)
- Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2 (Q29620608) (← links)
- Strategies to genetically engineer T cells for cancer immunotherapy (Q33655849) (← links)
- Emerging immunotherapeutics in adenocarcinomas: A focus on CAR-T cells (Q33833475) (← links)
- The basic principles of chimeric antigen receptor design (Q34036213) (← links)
- Recombinant human CD137L for cancer immunotherapy: effects of different fusions and linkers on its activity (Q34039129) (← links)
- CAR-modified T-cell therapy for cancer: an updated review. (Q34044213) (← links)
- Driving CAR T-cells forward (Q34046505) (← links)
- Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice (Q34245416) (← links)
- Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions (Q34248531) (← links)
- Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy (Q34550649) (← links)
- Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells (Q34553167) (← links)
- Engineering T cell function using chimeric antigen receptors identified using a DNA library approach (Q34717977) (← links)
- A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer. (Q34729692) (← links)
- T cells bearing a chimeric antigen receptor against prostate-specific membrane antigen mediate vascular disruption and result in tumor regression. (Q34893030) (← links)
- Immunotherapy for malignant glioma (Q35114086) (← links)
- Chimeric antigen receptors with mutated IgG4 Fc spacer avoid fc receptor binding and improve T cell persistence and antitumor efficacy (Q35399080) (← links)
- NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic ma (Q35605318) (← links)
- Cancer immunotherapy comes of age (Q35666338) (← links)
- Tumor-Targeted Human T Cells Expressing CD28-Based Chimeric Antigen Receptors Circumvent CTLA-4 Inhibition (Q35673845) (← links)
- Animal models and molecular imaging tools to investigate lymph node metastases (Q35720139) (← links)
- K12/SECTM1, an interferon-γ regulated molecule, synergizes with CD28 to costimulate human T cell proliferation (Q35787355) (← links)
- Evaluation of Intracellular Signaling Downstream Chimeric Antigen Receptors (Q35877585) (← links)
- L1 Cell Adhesion Molecule-Specific Chimeric Antigen Receptor-Redirected Human T Cells Exhibit Specific and Efficient Antitumor Activity against Human Ovarian Cancer in Mice (Q35892897) (← links)
- CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results (Q35953372) (← links)
- Chimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer (Q35980893) (← links)
- Transgelin-2 in B-Cells Controls T-Cell Activation by Stabilizing T Cell - B Cell Conjugates (Q36032528) (← links)
- Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma (Q36321176) (← links)
- Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies (Q36386891) (← links)
- Retargeted human avidin-CAR T cells for adoptive immunotherapy of EGFRvIII expressing gliomas and their evaluation via optical imaging (Q36414279) (← links)
- Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells (Q36470354) (← links)
- How do CARs work?: Early insights from recent clinical studies targeting CD19. (Q36476104) (← links)